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Abstract
Background: Antenatal anemia is a risk factor for adverse maternal and fetal outcomes and is prevalent in sub-Saharan
Africa. Less than half of antenatal anemia is considered responsive to iron; identifying women in need of iron may help
target interventions. Iron absorption is governed by the iron-regulatory hormone hepcidin.
Objective: We sought to characterize changes in hepcidin and its associations with indexes of iron stores, erythropoiesis, and
inflammation at weeks 14, 20, and 30 of gestation and to assess hepcidins diagnostic potential as an index of iron deficiency.
Methods: We measured hemoglobin and serum hepcidin, ferritin, soluble transferrin receptor (sTfR), and C-reactive protein
(CRP) at 14, 20, and 30wk of gestation in a cohort of 395 Gambianwomen recruited to a randomized controlled trial. Associations
with hepcidin were measured by using linear regression, and hepcidins diagnostic test accuracy [area under the receiver
operating characteristic curve (AUCROC), sensitivity, specificity, cutoffs] for iron deficiency at each time point was analyzed.
Results: The prevalence of anemia increased from 34.6% at 14 wk of gestation to 50.0% at 20 wk. Hepcidin
concentrations declined between study enrollment and 20 wk, whereas ferritin declined between 20 and 30 wk of
gestation. The variations in hepcidin explained by ferritin, sTfR, and CRP declined over pregnancy. The AUCROC values for
hepcidin to detect iron deficiency (defined as ferritin <15 mg/L) were 0.86, 0.83, and 0.84 at 14, 20, and 30 wk,
respectively. Hepcidin was superior to hemoglobin and sTfR as an indicator of iron deficiency.
Conclusions: In Gambian pregnant women, hepcidin appears to be a useful diagnostic test for iron deficiency and may
enable the identification of cases for whom iron would be beneficial. Hepcidin suppression in the second trimester suggests
a window for optimal timing for antenatal iron interventions. Hemoglobin does not effectively identify iron deficiency in
pregnancy. This trial was registered at www.isrctn.com as ISRCTN49285450. J Nutr 2017;147:1131–7.
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Introduction
More than 38% of pregnant women worldwide are anemic,
with the prevalence greatest in sub-Saharan Africa and parts of
Asia (1). In Africa and Asia, anemia directly or indirectly
contributes to one-quarter of maternal deaths (2). Consequences
of antenatal anemia include premature delivery and low birth
weight (3). Universal iron supplementation is recommended by
the WHO for all pregnant women in a setting where anemia
prevalence in this population exceeds 40% (4). However, only
half of anemia cases in pregnancy worldwide (including only
44% of cases in Africa and 47% of cases in Asia) are attributed
to iron deficiency and amenable to iron supplementation (1).
The use of iron to treat other causes of anemia (including
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malaria, inflammation, and hemoglobinopathy) may not be
beneficial, may represent a missed opportunity to identify and
treat an alternative condition, and in some cases, may be actively
harmful because it could exacerbate the risk of infection (5)
or iron overload (6). However, such cases would likely be
misdiagnosed and iron supplementation provided if a decision
for iron intervention was based on a diagnosis of anemia, or if
universal iron interventions are provided. Therefore, an appro-
priate case definition of iron deficiency in pregnancy could be of
value in correctly identifying women who would most benefit
from iron interventions.
Although there are several well-established tests for iron
status, accurate assessment with the use of a single test is difficult
(7, 8). Definitions of iron deficiency with the use of conventional
markers, such as ferritin, remain under review (9) and may
require adjustment for levels of inflammation. However,
deploying multiple tests in the field is complex and costly,
requires sophisticated interpretation, and is of limited value
in resource-poor settings (7, 10). A biomarker that enables
accurate diagnosis of iron status is needed.
Hepcidin, a peptide hormone produced by the liver, is the
master regulator of systemic iron homeostasis (11). Hepcidin
binds to the iron exporter ferroportin, inducing its internal-
ization and subsequent degradation (12). Hepcidin concen-
trations are suppressed in iron deficiency, facilitating
increased iron absorption and utilization, and elevated in
iron loading and inflammation, preventing access of iron to
the plasma. There is therefore considerable interest in pursu-
ing hepcidin as a diagnostic test for iron status (13). We have
previously found that hepcidin is a promising tool to identify
individuals who might gain the most benefit from iron
supplementation and defined putative thresholds that could
help define iron deficiency in young children (14) and in
women (15).
Small longitudinal studies showed that hepcidin is sup-
pressed in pregnancy (16), likely facilitating the recognized
increase in iron absorption seen during this period (17).
Whether hepcidin suppression is mediated chiefly by iron
deficiency (18) or maternal or fetal erythropoiesis, or another
fetal, placental, or maternal factor, is currently unclear (16).
Experimental data indicate that hepcidin may be directly
transcriptionally regulated by estrogen and that steroid hor-
mones may directly upregulate hepcidin expression (19, 20).
The value of hepcidin as an index for iron deficiency in
pregnancy has not been previously established, and putative
cutoffs have not been defined. In a longitudinal cohort of pregnant
Gambian women, we sought to evaluate associations between
variables of maternal iron status and erythropoiesis with hepcidin
at 3 distinct time periods and then to determine the diagnostic test
accuracy and estimate potential cutoffs of hepcidin as an index of
iron deficiency.
Methods
Participants and study design. Samples were derived from the Early
Nutrition and Immune Development (ENID)9 trial in rural Gambia,
which is a randomized trial assessing whether nutritional supplemen-
tation to pregnant women and their infants can enhance infant
immune development (trial registration: ISRCTN49285450) (21). For
the main ENID trial, all of the women in the 36 villages who were
registered within the West Kiang Demographic Surveillance System
and aged between 18 and 45 y were invited from February 2010 to
January 2013 to participate in the study. Women with confirmed
pregnancy between 10 and 20 wk by ultrasound were randomly
assigned to 1 of 4 intervention groups: 1) iron-folic acid (standard
care), 2) multiple micronutrients (including iron-folic acid), 3)
protein energy plus iron-folic acid, and 4) protein energy plus
multiple micronutrients (including iron-folic acid). Women who
were 1) currently beyond 20 wk of gestation at the first clinic
attendance (by ultrasound), 2) enrolled in another study, 3) severely
anemic at recruitment (hemoglobin <7 g/dL), or 4) menopausal were
excluded. Samples from the first 400 women recruited to the ENID
trial were included in this analysis. Thus, all of the participants in this
substudy analysis received 60 mg Fe and 400 mg folic acid/d as part of
the ENID intervention, from enrollment to delivery, as per current
WHO guidelines (4, 21). The national prevalence of anemia in
pregnancy was estimated at 67.9% (22). It would therefore not have
been ethical to deny iron to women in pregnancy given the established
benefits from iron supplementation.
Analytical methods. Maternal blood samples collected at enrollment
(booking) of mean gestational ages of 14, 20, and 30 wk of gestation
were used for sample analysis. All of the samples were collected after an
overnight fast, before 0900. Hemoglobin was analyzed from whole-
blood samples by using a Medonic M-Series automated hematology
analyzer (Boule Medical) shortly after sample collection. Serum ferritin,
soluble transferrin receptor (sTfR), iron, and C-reactive protein (CRP)
were analyzed from serum samples by using an automated biochemistry
analyzer (COBAS Integra 400 plus; Roche Diagnostics). Serum hepcidin
was quantified on the same samples by using a competitive ELISA
(Bachem Hepcidin-25; now marketed by Peninsula Laboratories Inter-
national), with a detection range of 0.049–25 ng/mL. Concentrations
were interpolated from a 4-parameter curve fitted from a 2-fold,
10-point serial dilution made from a manufacturer-provided standard
peptide. Samples outside the standard curve were re-analyzed at a higher
dilution, and the final concentration was calculated on the basis of the
dilution factor (23). The concentrations were obtained from the standard
curve by using Dynex Revelation software (Dynex Technologies).
Hepcidin measurements were performed in duplicate. All of the analyses
were performed in the MRC (Medical Research Council) Keneba
Laboratory. Results of conventional iron indexes were not available to
staff measuring hepcidin, and vice versa.
Statistical analysis. Variables were summarized at each time point,
and means or proportions between time points compared by using t
tests or 2-sample tests of proportions (2-sided, a = 0.05; significance
defined as P < 0.05). Next, we modeled determinants of hepcidin
concentrations at each of the 3 time points with the use of multiple
linear regression, with variables log-transformed if the distribution was
skewed. We estimated b-coefficients (which normalize the mean and
SD), enabling comparison of associations between variables. We then
generated nonparametric receiver operating characteristic curves
(ROCs) and calculated the AUCROC together with Bamber and Hanley
CIs for hepcidin concentration as a test of iron deficiency as defined by
2 recognized reference standards: 1) serum ferritin <15 mg/L (24) and 2)
estimated body iron stores <0 mg/kg (based on the ratio of sTfR and
ferritin) (10). The sensitivity and specificity of hepcidin as an index of iron
deficiency were determined for each possible cutoff for hepcidin. We
calculated the Youden index [(sensitivity/100 + specificity/100) 2 1] at
each value of hepcidin to assist in the selection of an optimal cutoff.
Missing data were analyzed by list-wise deletion. The sample size of the
study was predicated on the size of the cohort. Analyses were undertaken
by using Stata 13 (StataCorp).
Ethics. Informed consent (including permission to undertake future
related analysis of the samples) was obtained from all participants
through either a signature or a thumbprint. The ENID trial was
approved by the Gambia Government/MRC Unit The Gambia joint
ethics committee (SCC1126v2).
9 Abbreviations used: CRP, C-reactive Protein; ENID, Early Nutrition and Immune
Development; IDA, iron deficiency anemia; ROC, receiver operating character-
istic curve; sTfR, soluble transferrin receptor.
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Results
Samples from a total of 395 pregnant women were analyzed at
recruitment (;14 wk of gestation) and at 20 and 30 wk of
gestation (Table 1). The mean age of the women was 29.6 y
(95% CI: 29.1, 30.3), mean weight was 54.9 kg (95% CI: 53.9,
55.9 kg), mean height was 161.4 cm (95%CI: 160.9, 162.1 cm),
and mean BMI (in kg/m2) was 21.0 (95% CI: 20.6, 21.3).
Hematologic and iron indexes at each time point are shown in
Table 1. Hepcidin concentrations were lower at 20 wk than at
14 wk and even lower at 30 wk of gestation. Hemoglobin
declined from 14 wk through 30 wk of gestation, whereas serum
ferritin decreased, sTfR increased, and hence total body iron
declined, between 20 and 30 wk of gestation. CRP increased
significantly between 14 and 20 wk of gestation.
The prevalence of anemia, iron deficiency, and inflammation
across pregnancy is presented in Table 2. The prevalence of
anemia was 34.6% at 14 wk and increased to 50.0% at 20 wk
and remained stable thereafter. Iron deficiency defined as ferritin
<15 mg/L was 37.6% at 14 wk and 34.3% at 20 wk, increasing
to 50.6% at 30 wk of gestation. Iron deficiency defined as body
iron <0mg/kg was 27.35%, 24.78%, and 35.05% at 14, 20, and
30 wk of gestation, respectively. The prevalence of elevated sTfR
likewise increased between 20 and 30 wk. The prevalences of
iron deficiency anemia (anemia and low ferritin) were 18.8%,
20.16%, and 32.83% at 14, 20, and 30 wk of gestation,
respectively. Thus, these data indicate that the prevalence of
anemia increases during the second trimester of pregnancy,
whereas the prevalence of iron deficiency increases between the
second and early third trimester.
Changes in concentrations of hepcidin and iron indexes at
different gestation durations led us to evaluate the relation
between hepcidin and these variables at each time point. Thus,
we undertook multiple linear regression to compare associations
between hepcidin at each of the 3 time points with 3 factors
likely to influence it: ferritin (reflecting iron stores), sTfR
(reflecting tissue iron demand including erythropoiesis), and
CRP (reflecting inflammation). We used standardized coeffi-
cients to enable comparison in slope and the strength of
association between each variable at each time point. As shown
in Table 3, the slope of association between hepcidin and ferritin
diminished over the course of pregnancy, whereas the associa-
tion between hepcidin and sTfR was strengthened. Finally, the
overall amount of variation in hepcidin explained by these
variables diminished over the course of pregnancy.
We then graphed the ROC curves and estimated AUCROC for
hepcidin to detect iron deficiency. With the use of a standard
definition of iron deficiency of ferritin <15 mg/L, the AUCROC
values for hepcidin to detect iron deficiency were 0.86, 0.83, and
0.84 at 14, 20, and 30 wk, respectively. With the use of body
iron <0 mg/kg, the AUCROC values for hepcidin to detect iron
deficiency were 0.85, 0.86, and 0.80 at 14, 20, and 30 wk,
respectively. During pregnancy, iron supplementation should be
routinely administered when body iron stores and dietary iron
cannot meet maternal, fetal, and placental demands (4, 25).
However, hemoglobin remains the most commonly deployed
initial test to determine the need for treatment doses of iron in
pregnancy (26), even though it is a test for anemia rather than
iron deficiency per se, because the conditions have often been
considered synonymous (27). sTfR is another increasingly
widely available index of iron status. We therefore compared
the capacity of hepcidin with hemoglobin concentration and
sTfR to detect iron deficiency (defined by low body iron
stores) and found that hepcidin was superior to hemoglobin at
14 and 20 wk, and similar at 30 wk, and was superior to sTfR
at each time point when using ferritin alone as a gold standard
(Figure 1).
Sensitivity, specificity, and the Youden index for a range of
potential hepcidin cutoffs are shown in Table 4. Hepcidin
appears to have an optimal cutoff (based on the tradeoff
between sensitivity and specificity calculated by the Youden
index) that fluctuates over the duration of pregnancy (from
1.5–2.0 ng/mL at booking, to 0.5 ng/mL at 20 wk, to 1.0–
1.5 ng/mL by 30 wk). However, these lower thresholds are
associated with reductions in sensitivity. The prevalence of iron
deficiency at each hepcidin threshold is presented in Supple-
mental Table 1.
Discussion
In this longitudinal study in pregnant women, we measured
hepcidin concentrations together with traditional iron bio-
markers, investigated the changes that occurred between 14 and
30 wk of gestation, and assessed the diagnostic performance of
hepcidin for iron deficiency. We observed that hepcidin concen-
trations decreased by 20 wk of gestation, whereas iron stores
(measured by ferritin and body iron stores) declined most
substantially at 30 wk of gestation. These changes occurred
despite the distribution of routine iron supplementation to all of
TABLE 1 Iron and hematologic indexes in pregnant Gambian women1
Index 14 wk 20 wk P 30 wk P
n 395 375 367
Gestational age, wk 14.1 (8.0, 21.3) 20.4 (15.0, 26.9) 30.5 (25.4, 34.4)
Hemoglobin, g/dL 11.55 (7.2, 17.9) 11.00 (7.4, 14.5) ,0.001 10.77 (6.2, 14.4) ,0.0001
MCV, fL 81.9 (60.9, 98.6) 83.8 (62.9, 104.0) ,0.001 83.6 (61.8, 99) NS
Serum ferritin, μg/L 20.69 (0.1, 237.2) 19.20 (0.1, 273.8) NS 14.29 (0.1, 315.5) ,0.001
Serum sTfR, mg/L 4.41 (0.58, 17.97) 4.25 (1.12, 15.42) NS 4.80 (1.49, 17.81) ,0.001
Serum sTfR-F index 3.29 (214.80, 111.63) 3.26 (25.63, 56.43) NS 3.86 (287.19, 76.26) NS
Serum CRP, mg/L 1.70 (0.02, 43.48) 2.41 (0.00, 59.32) 0.001 2.29 (0.01, 126.68) NS
Total body iron, mg/kg 2.70 (218.38, 14.40) 2.50 (217.57, 14.06) NS 1.18 (217.84, 11.02) ,0.001
Serum hepcidin, ng/L 1.59 (0.03, 49.79) 1.23 (0.02, 45.70) 0.006 1.09 (0.04, 135.69) NS
1 Values are arithmetic (hemoglobin, MCV, sTfR, CRP, and total body iron) or geometric (ferritin, sTfR-F index, and hepcidin) means
(ranges). P values are for 2-sided paired t tests comparing analytes between 14 and 20 wk and between 20 and 30 wk of gestation. CRP,
C-reactive protein; MCV, mean cell volume; sTfR, soluble transferrin receptor; sTfR-F index, sTfR/log10 (ferritin).
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the women in the cohort. We observed that hepcidin performs
well as a diagnostic test for iron deficiency, and indeed
outperforms hemoglobin at all time points. On the basis of the
AUCROC, the diagnostic performance of hepcidin to detect iron
deficiency was good (AUCROC >0.80) and was similar from 14
to 30 wk of gestation.
Few studies, to our knowledge, have previously reported on
hepcidin concentrations during human pregnancy, and those
that did generally included relatively small sample sizes. Van
Santen et al. (28) measured hepcidin in 31 women across the 3
trimesters of pregnancy and observed that hepcidin concentra-
tions decreased from the second trimester of pregnancy and
became essentially undetectable by the third trimester; hepcidin
concentrations correlated with iron status. A study in 37 Danish
women receiving iron supplementation in pregnancy likewise
found that hepcidin concentrations were suppressed during
pregnancy, occurring between the first measurement at 13–20 wk
and the second measurement at 21–28 wk; hepcidin concentra-
tions were observed to remain suppressed during pregnancy and
to increase at delivery and thereafter (29). In contrast, Simavli
et al. (30) measured hepcidin concentrations across pregnancy in
healthy Turkish women and observed no reduction in hepcidin
across pregnancy, nor an association between hepcidin and iron
status. Interestingly, in a similar study, the authors found evidence
that elevated hepcidin in the second trimester may be associated
with adverse pregnancy outcomes, such as pre-eclampsia and
intrauterine growth retardation (31). The importance of hepcidin
in facilitating increased iron absorption was confirmed in a stable
isotope iron study that showed a correlation between maternal
hepcidin concentrations and maternal iron absorption and
transfer of iron to the neonate (32).
By studying hepcidin concentrations across gestation in a
large cohort of women with uncomplicated singleton pregnan-
cies, all of whom were randomly assigned to receive iron
supplementation, in a population at high risk of anemia, we
confirm that hepcidin concentrations decline by 20 wk of
pregnancy, before the onset of biochemical evidence of iron
deficiency or clear evidence of changes in iron stores (assessed by
ferritin, sTfR, and total body iron). Conversely, the reduction in
iron stores observed between 20 and 30 wk of pregnancy was
not accompanied by a further reduction in hepcidin concentra-
tions. At all times in pregnancy, hepcidin is associated with
ferritin, sTfR, and CRP, but the proportion of variation in
hepcidin attributable to these factors decreases during gestation.
These findings suggest that iron deficiency itself is not solely
responsible for the reduction in hepcidin during pregnancy and
raise the possibility of an additional, as yet unidentified,
regulator of hepcidin concentrations during pregnancy. The
expansion of maternal erythropoiesis with the expression of the
erythroid-derived hepcidin-suppression hormone erythroferrone
represents one hypothesis (33), which is supported by the
increasing regression coefficient between hepcidin and sTfR
(an indicator of RBC production) as pregnancy progresses.
Alternatively, an as-yet-undiscovered placenta- or fetus-derived
factor may act to suppress hepcidin expression in the maternal
liver. Estrogen and progesterone appear to upregulate hepcidin
transcription in cellular and animal models (20), but their role
in regulating iron homeostasis in human pregnancy requires
further investigation. The expansion of plasma volume during
pregnancy causes reductions in concentrations of many ana-
lytes, including hemoglobin (hemodilution), and has been
considered a potential mechanism for reductions in concentra-
tions of ferritin (34). However, such a mechanism would not
explain concordant increases in concentrations of sTfR,
suggesting that the changes in measured iron status are related
to changes in iron stores and metabolism, rather than exclusively
to hemodilution.
The suppression of serum hepcidin is an essential part of the
physiologic response to iron need, and pregnant women with
TABLE 2 Prevalence of anemia, iron deficiency, and inflammation at 14, 20, and 30 wk of gestation in
pregnant Gambian women1
Condition 14 wk 20 wk P 30 wk P
Anemia, n/total n 135/390 189/378 ,0.001 201/368 0.207
Hemoglobin ,11 g/dL, % (95% CI) 34.62 (30.04, 39.50) 50.00 (44.95, 55.04) 54.62 (49.47, 59.66)
Iron deficiency, n/total n 145/385 117/341 0.348 159/314 ,0.0001
Ferritin ,15 μg/L, % (95% CI) 37.66 (32.93, 42.63) 34.31 (29.43, 39.53) 50.64 (45.09, 56.16)
IDA, n/total n 70/387 73/362 0.470 110/335 ,0.001
Anemia + low ferritin, % (95% CI) 18.09 (14.54, 22.26) 20.16 (16.33, 24.64) 32.83 (27.99, 38.07)
Elevated sTfR, n/total n 152/382 118/347 0.106 133/310 0.019
sTfR .4.4 mg/L, % (95% CI) 39.79 (34.97, 44.80) 34.01 (29.18, 39.17) 42.90 (37.47, 48.50)
Absent body iron, n/total n 102/373 84/339 0.436 102/291 0.005
,0 mg/kg, % (95% CI) 27.35 (23.04, 32.11) 24.78 (20.45, 29.67) 35.05 (29.75, 40.74)
Inflamed, n/total n 83/375 100/345 0.035 69/302 0.076
CRP .5 mg/L, % (95% CI) 22.13 (18.20, 26.63) 28.99 (24.41, 34.02) 22.85 (18.43, 27.95)
1 P values are for 2-sided tests of proportion comparing proportions between 14 and 20 wk and between 20 and 30 wk of gestation. CRP, C-
reactive protein; IDA, iron deficiency anemia; sTfR, soluble transferrin receptor; sTfR-F index, sTfR/log10 (ferritin).
TABLE 3 Factors associated with (log) hepcidin at 14, 20, and
30 wk of gestation in pregnant Gambian women by multiple
regression1
14 wk P 20 wk P 30 wk P
Ferritin 0.60 ,0.001 0.51 ,0.001 0.42 ,0.001
sTfR 20.16 ,0.001 20.23 ,0.001 20.33 ,0.001
CRP 0.04 0.327 0.02 0.696 0.07 0.139
Overall r2 0.48 0.40 0.39
1 Values are b-coefficients (regression coefficients adjusted for a mean and SD of 1)
and P values for association. CRP, C-reactive protein; sTfR, soluble transferrin
receptor.
1134 Bah et al.
Downloaded from https://academic.oup.com/jn/article-abstract/147/6/1131/4669675
by London School of Hygiene & Tropical Medicine user
on 26 January 2018
undetected concentrations of serum hepcidin transfer dietary
iron to their fetus more effectively (32). As the direct regulator of
systemic iron homeostasis through its role in governing cellular
iron export, and hence absorption across the enterocyte (12),
hepcidin is an intriguing candidate as a potential guide to
determine which individuals should be considered for iron
interventions. Our data indicate a hepcidin threshold with the use
of this assay that fluctuates over pregnancy, from between 1.5 and
2.0 ng/mL at 14 wk to lower thresholds at 30 wk of gestation;
reductions in these cutoffs are associated with improved
specificity but come at the necessary expense of sensitivity.
Importantly, reductions in hepcidin concentrations in pregnancy
FIGURE 1 ROCs and the corresponding AUCROC values for hepcidin as a test for iron deficiency defined by 2 reference standards in pregnant
Gambian women. (A–C) Capacity of hepcidin to detect iron deficiency as defined by ferritin,15 mg/L at 14 (A), 20 (B), and 30 wk (C) of gestation,
respectively; the performance of hepcidin is compared with sTfR and hemoglobin. (D–F) Capacity of hepcidin to detect iron deficiency defined by
body iron stores ,0 mg/kg at 14 (D), 20 (E), and 30 wk (F) of gestation, respectively; the performance of hepcidin is compared with hemoglobin.
ROC, receiver operating characteristic curve; sTfR, soluble transferrin receptor.
TABLE 4 Sensitivity, specificity, and the Youden index at putative hepcidin thresholds at each time point in pregnancy in pregnant
Gambian women1
Hepcidin cutoff, ng/mL
14 wk 20 wk 30 wk
Sensitivity Specificity Youden Sensitivity Specificity Youden Sensitivity Specificity Youden
Ferritin ,15 μg/L as standard
0.16 42.1 93.3 0.354 60 89.7 0.497 52.2 90.9 0.431
0.5 56.6 87.9 0.445 72.2 81.7 0.539 69.2 85.1 0.543
1.0 76.6 81.3 0.579 79.1 71.4 0.505 76.1 80.5 0.566
1.5 84.1 77.1 0.612 80 65.2 0.452 83.6 76 0.596
2.0 88.3 70.8 0.591 83.5 59.4 0.429 85.5 70.1 0.556
2.5 93.1 66.3 0.594 86.1 52.2 0.383 86.2 64.9 0.511
3.0 93.8 62.1 0.559 89.6 48.2 0.378 88.7 59.7 0.484
Total body iron ,0 mg/kg as standard
0.16 50 90.4 0.404 69.5 86.3 0.558 58.8 82 0.408
0.5 63.7 83.4 0.471 85.4 78.8 0.642 78.4 74.6 0.530
1.0 82.4 74.2 0.566 90.2 68.6 0.588 84.3 69.3 0.536
1.5 87.3 68.6 0.559 90.2 62.7 0.529 88.2 61.9 0.501
2.0 91.2 83.9 0.751 92.7 56.9 0.496 90.2 56.6 0.468
2.5 95.1 57.6 0.527 95.1 50.2 0.453 91.2 52.4 0.436
3.0 95.1 53.5 0.486 95.1 45.1 0.402 95.1 48.1 0.432
1 Sensitivity = true positive detection rate; specificity = true negative detection rate; Youden index = (sensitivity/100 + specificity/100)2 1 for each time point by using the 2 gold
standards of iron deficiency considered.
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reflect a physiologic state of high iron requirement. Thus,
although low hepcidin concentrations likely appropriately
identify individuals in whom iron supplementation may be
beneficial, it is unclear whether depriving women of iron
supplements on the basis of hepcidin concentrations that are
low but above the threshold we identified is beneficial. Given the
established benefits from iron supplements on maternal and
child health and the paucity of data indicating that iron is
harmful in this group (35), it may be reasonable to use a higher
hepcidin threshold to identify women in whom iron should be
withheld, which is more ‘‘sensitive.’’ This would need to be
confirmed in prospective studies. Our data indicate that hepcidin
generally outperforms hemoglobin measurement as an index of
iron deficiency, reinforcing the concept that hemoglobin testing
alone is not an adequate approach to determining iron stores and
the need for iron interventions. As we showed previously in
children (14), testing for anemia is an inaccurate approach for
the detection of iron deficiency. However, in both high-income
(36) and low-income (37) settings, individual decisions to treat
iron deficiency are routinely based on hemoglobin, rather than
on iron deficiency testing. In population health, the dose of iron
for the universal distribution of iron interventions is based on the
prevalence of anemia, not iron deficiency (4). Our data suggest
that measurement of an iron variable (including hepcidin) may
better guide individual or public health approaches. Although
rural Gambia is a malaria-endemic region, recent data from both
the health center and community surveys showed that malaria
endemicity in The Gambia is now low, heterogeneous, and
seasonal (38), and malaria did not affect this cohort. Approx-
imately one-fifth of the cohort had inflammation as defined by
CRP >5 mg/L. CRP did not correlate with hepcidin in this
population, indicating that inflammation was not an important
regulator of hepcidin in these women. However, CRP-based
definitions of inflammation are indistinct in pregnancy because
CRP is elevated over the course of gestation (39) and may hence
be an imperfect biomarker for inflammation in this context.
To our knowledge, the diagnostic performance of hepcidin to
detect iron deficiency has not been previously evaluated in
pregnancy. However, studies in nonpregnant women found
hepcidin to be a promising indicator of iron deficiency. When
hepcidin was compared with the sTfR/log10 (ferritin) index as a
standard, hepcidin showed an AUCROC of 0.89, and when
compared with ferritin, it showed an AUCROC of 0.87 (15).With
the use of the same hepcidin ELISA kit as the current study
(Bachem), we assessed the diagnostic performance of hepcidin as
an index of iron deficiency and the need for iron supplementa-
tion in West and East African preschool children and found that
the AUCROC for hepcidin to identify iron deficiency was 0.85,
with a threshold that used the Bachem ELISA of 5.5 ng/mL to
distinguish iron deficiency across the overall population and
among anemic children (14). Given the suppression of hepcidin
concentrations in pregnancy, it is unsurprising that a lower
optimal threshold would be identified in this population. There
are several assays available for hepcidin measurement, which use
ELISA or MS methodology. Hepcidin concentrations measured
by these different assays are correlated but differ in absolute
values (40). If hepcidin assays could be harmonized, the
thresholds identified by our study may serve as a platform
for a value that could be used to detect iron deficiency in
pregnancy. A key advantage of hepcidin measurement is that it
directly interrogates systemic iron handling, and hence predicts
absorption and utilization of ingested iron (41). Given that
hepcidin transcription is directly regulated by iron stores,
erythropoiesis, and inflammation (42), hepcidin measurements
represent the net integration of these signals, which currently
have to be measured by individual biomarkers [e.g., ferritin,
hemoglobin (or sTfR), and CRP or a1-glycoprotein, respec-
tively]. Thus, a single biomarker may be able to replace multiple
indexes, which may obviate the costs associated with the more
current, relatively expensive assays.
Our study compares hepcidin with established reference
standards frequently recommended for the diagnosis of iron
deficiency in pregnancy. However, the optimal ferritin thresholds
used to define iron deficiency remain uncertain and continue to
be reviewed (9). Validation of iron deficiency in a large field
study with gold-standard assessments, such as measurement of
bone marrow iron stores or stable isotope iron incorporation,
would not have been achievable, and hence our analysis
represents the most pragmatic approach. Factors beyond
changes in body iron stores, such as plasma dilution, could
potentially explain reductions in ferritin over the course of
pregnancy; however, these effects are unlikely to explain the
changes in both hepcidin and ferritin because reductions in the
biomarkers were seen at different time intervals (whereas
hemoglobin declined constantly from 14 to 30 wk). Changes
in transferrin saturation may acutely modulate hepcidin expres-
sion, but we were unable to include these data in this study (43).
An improved understanding of the complex and distinctive
mechanisms of regulation of iron absorption, utilization, and
transfer during pregnancy will enable improved targeting of
clinical and public health interventions. Our data show the
suppression of hepcidin concentrations among pregnant rural
women by 20 wk of gestation, in advance of the onset of low
iron stores, and suggest a window at the commencement of the
second trimester before iron stores have declined when iron
utilization may be greatest. In this population, the commonly
used approach of identifying participants in need of iron
treatment by screening for anemia (by measuring hemoglobin)
is only modestly accurate. Associations between hepcidin and
iron stores are maintained, although modified, across pregnancy
and are reflected by the capacity of hepcidin to distinguish
individuals in the population with iron deficiency. An approach
for hepcidin-directed iron supplementation in both pregnant
women and children is currently being tested in the field (44, 45).
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